Abstract
Nutrient perception in the gut is important for the maintenance of nutrient and energy balance in the body. Recently, nutrient perception has attracted the attention of medical researchers, as it may provide an opportunity to prevent obesity and associated disease. Recent progress in functional MRI (fMRI) techniques have enabled noninvasive investigation of whole brain function during the processing of information regarding ingested nutrients from the gut depending on the feeding status in both rodents and human subjects. However, the fMRI technique still has substantial problems because it relies on blood oxygenation levels. Here, a novel fMRI technique is introduced that solves this problem for rodent fMRI studies and fMRI studies of the gut-brain axis.
Keywords: Functional MRI, chemoreception, gastrointestinal tract, vagus nerve, gut hormone.
Current Pharmaceutical Design
Title:Neuroimaging of Gut Nutrient Perception
Volume: 20 Issue: 16
Author(s): Tomokazu Tsurugizawa
Affiliation:
Keywords: Functional MRI, chemoreception, gastrointestinal tract, vagus nerve, gut hormone.
Abstract: Nutrient perception in the gut is important for the maintenance of nutrient and energy balance in the body. Recently, nutrient perception has attracted the attention of medical researchers, as it may provide an opportunity to prevent obesity and associated disease. Recent progress in functional MRI (fMRI) techniques have enabled noninvasive investigation of whole brain function during the processing of information regarding ingested nutrients from the gut depending on the feeding status in both rodents and human subjects. However, the fMRI technique still has substantial problems because it relies on blood oxygenation levels. Here, a novel fMRI technique is introduced that solves this problem for rodent fMRI studies and fMRI studies of the gut-brain axis.
Export Options
About this article
Cite this article as:
Tsurugizawa Tomokazu, Neuroimaging of Gut Nutrient Perception, Current Pharmaceutical Design 2014; 20 (16) . https://dx.doi.org/10.2174/13816128113199990580
DOI https://dx.doi.org/10.2174/13816128113199990580 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Current Neuropharmacology Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats
Current Neurovascular Research Zebrafish as an Animal Model to Study Epileptic Seizures and Epileptic Syndromes
Current Psychopharmacology Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Study of Some Piperine Analogues on Drugs Efflux by Targeting P-glycoprotein, an in silico Approach
Letters in Drug Design & Discovery Herbal and Holistic Solutions for Neurodegenerative and Depressive Disorders: Leads from Ayurveda
Current Pharmaceutical Design Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses
Current Pharmacogenomics Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Lack of Data on Depression-like States and Antidepressant Pharmacotherapy in Patients with Epilepsy: Randomised Controlled Trials are Badly Needed
Current Pharmaceutical Design Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Role of Noradrenergic and Orexinergic Neurons in General Anesthesia
Current Neuropharmacology Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology